Kura Oncology (KURA) Competitors

Kura Oncology (NASDAQ:KURA) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership, community ranking and dividends.

Does the MarketBeat Community favor KURA or NAMS?

Kura Oncology received 411 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 90.91% of users gave NewAmsterdam Pharma an outperform vote while only 69.78% of users gave Kura Oncology an outperform vote.

Company	Underperform	Outperform
Kura Oncology	Outperform Votes 441 69.78%	Underperform Votes 191 30.22%
NewAmsterdam Pharma	Outperform Votes 30 90.91%	Underperform Votes 3 9.09%

Is KURA or NAMS more profitable?

NewAmsterdam Pharma's return on equity of 0.00% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	N/A	-44.09%	-39.57%
NewAmsterdam Pharma	N/A	N/A	N/A

Which has more volatility and risk, KURA or NAMS?

Kura Oncology has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of -0.03, meaning that its stock price is 103% less volatile than the S&P 500.

Does the media prefer KURA or NAMS?

In the previous week, NewAmsterdam Pharma had 19 more articles in the media than Kura Oncology. MarketBeat recorded 29 mentions for NewAmsterdam Pharma and 10 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 0.98 beat NewAmsterdam Pharma's score of 0.53 indicating that Kura Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	10 Very Positive mention(s)	1 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals have more ownership in KURA or NAMS?

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 6.4% of Kura Oncology shares are owned by insiders. Comparatively, 20.8% of NewAmsterdam Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Do analysts recommend KURA or NAMS?

Kura Oncology currently has a consensus target price of $24.50, indicating a potential upside of 254.05%. NewAmsterdam Pharma has a consensus target price of $43.00, indicating a potential upside of 109.76%. Given Kura Oncology's higher possible upside, equities analysts clearly believe Kura Oncology is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.93
NewAmsterdam Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has stronger earnings & valuation, KURA or NAMS?

Kura Oncology has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.99M	8.81	-$152.63M	-$2.10	-3.30
NewAmsterdam Pharma	$47.14M	48.82	-$176.94M	-$1.88	-10.90

Summary

Kura Oncology and NewAmsterdam Pharma tied by winning 9 of the 18 factors compared between the two stocks.